Ketamine in post-stroke depression: a report of 2 cases
Adam Włodarczyk, Jakub Słupski, Joanna Szarmach, D Milewska, Wiesław Jerzy Cubała
Frontiers in Psychiatry December 4, 2025 DOI: 10.3389/fpsyt.2025.1680687 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant post-stroke depression |
| Intervention | Ketamine |
| Topics | Ketamine Depression Esketamine |
| Keywords | Anesthesia Clinical trial Medline |
| Key findings | Ketamine may be a viable treatment option for patients with treatment-resistant post-stroke depression. |
Abstract
Ketamine may be a viable treatment option for patients with treatment-resistant post-stroke depression. Further research is warranted to better understand the efficacy and safety of ketamine in this specific patient population.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |